Literature DB >> 24899496

[New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer].

A K Höhn1, J Einenkel, C Wittekind, L-C Horn.   

Abstract

During recent years paramount changes have occurred in the pathogenesis of ovarian cancer and recent clinical studies identified new prognostic factors. Consequently, the FIGO has established a new staging system collectively covering carcinomas derived from the ovaries, the fallopian tubes and primary peritoneal cancers as well as malignant ovarian germ cell and sex-cord stromal tumors. The new staging system started on 01 January 2014. Major changes occurred in the FIGO IC/T1c stage with surgical spill (FIGO IC1/T1c1) versus capsule ruptured before surgery or tumor on ovarian or fallopian tube surface (FIGO IC2/T1c2) versus malignant cells in the ascites or peritoneal washings (FIGO IC3/T1c3). The regional lymph node metastases were subcategorised using a cut-off value of 10 mm as the largest dimension of the metastatic deposits. Distant metastases (excluding peritoneal metastases) were substaged as FIGO IVA/M1a in cases of cytologically or histologically proven pleural involvement and as FIGO IVB/M1b in cases of parenchymal metastases and metastases in extra-abdominal organs (including lymph nodes outside the peritoneal cavity and the inguinal lymph nodes).

Entities:  

Mesh:

Year:  2014        PMID: 24899496     DOI: 10.1007/s00292-014-1908-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

1.  Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B.

Authors:  G Ferrandina; G Scambia; F Legge; M Petrillo; V Salutari
Journal:  Gynecol Oncol       Date:  2007-07-05       Impact factor: 5.482

2.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

Review 3.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

4.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Angelo Maggioni; Neville Hacker; Fabio Landoni; Sven Ackermann; Elio Campagnutta; Karl Tamussino; Raimund Winter; Antonio Pellegrino; Stefano Greggi; Roberto Angioli; Natalina Manci; Giovanni Scambia; Tiziana Dell'Anna; Roldano Fossati; Irene Floriani; Rita S Rossi; Roberto Grassi; Giuseppe Favalli; Francesco Raspagliesi; Diana Giannarelli; Luca Martella; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2005-04-20       Impact factor: 13.506

5.  The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival.

Authors:  K Kanazawa; T Suzuki; M Tokashiki
Journal:  Gynecol Oncol       Date:  1999-05       Impact factor: 5.482

6.  Differences in tumor type in low-stage versus high-stage ovarian carcinomas.

Authors:  Martin Köbel; Steve E Kalloger; David G Huntsman; Jennifer L Santos; Kenneth D Swenerton; Jeffrey D Seidman; C Blake Gilks
Journal:  Int J Gynecol Pathol       Date:  2010-05       Impact factor: 2.762

7.  A new prognostic model for FIGO stage 1 epithelial ovarian cancer.

Authors:  Andreas Obermair; Arlan Fuller; Elisa Lopez-Varela; Toon van Gorp; Ignace Vergote; Lynne Eaton; Jeff Fowler; Michael Quinn; Ian Hammond; Donald Marsden; Anthony Proietto; Jonathan Carter; Margaret Davy; Lee Tripcony; Nadeem Abu-Rustum
Journal:  Gynecol Oncol       Date:  2006-11-07       Impact factor: 5.482

8.  RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.

Authors:  Georgina L Ryland; Sally M Hunter; Maria A Doyle; Simone M Rowley; Michael Christie; Prue E Allan; David D L Bowtell; Kylie L Gorringe; Ian G Campbell
Journal:  J Pathol       Date:  2013-02       Impact factor: 7.996

9.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

Review 10.  [Histologic classification and morphologic prognostic factors in malignant ovarian tumors].

Authors:  L C Horn; K Fricke; J Krugmann
Journal:  Zentralbl Gynakol       Date:  1995
View more
  7 in total

1.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

2.  [Gynecological tumors of the true pelvis: Radiological diagnosis for pelvic tumors made simple].

Authors:  M Meissnitzer; T Meissnitzer; R Forstner
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

Review 3.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

4.  Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Authors:  I Meinhold-Heerlein; C Fotopoulou; P Harter; C Kurzeder; A Mustea; P Wimberger; S Hauptmann; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

5.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

Review 6.  Update on Imaging of Ovarian Cancer.

Authors:  Rosemarie Forstner; Matthias Meissnitzer; Teresa Margarida Cunha
Journal:  Curr Radiol Rep       Date:  2016-04-09

7.  Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer: An Age-Stratified Study of 1123 Women from the FRANCOGYN Group.

Authors:  Yolaine Joueidi; Ludivine Dion; Sofiane Bendifallah; Camille Mimoun; Alexandre Bricou; Krystel Nyangoh Timoh; Pierre Collinet; Cyril Touboul; Lobna Ouldamer; Henri Azaïs; Yohann Dabi; Cherif Akladios; Geoffroy Canlorbe; Pierre-Adrien Bolze; Hélène Costaz; Mathieu Mezzadri; Tristan Gauthier; Frederic Kridelka; Pauline Chauvet; Nicolas Bourdel; Martin Koskas; Xavier Carcopino; Emilie Raimond; Olivier Graesslin; Lise Lecointre; Marcos Ballester; Cyrille Huchon; Jean Levêque; Vincent Lavoué
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.